“Technical but fundamental errors” lead to retraction of brain tumor paper

The journal Neuro-Oncology has retracted a 2011 paper by a group of researchers in Japan who had purported to find a genetic mechanism for how fluorescence can be used to diagnose certain brain tumors.

The paper, “Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA–induced fluorescence,” reported measurements using quantitative real-time (qRT)-PCR.

As the retraction notice explains:

Nanotech researcher SK Sahoo notches fifth retraction

Nanotech researcher SK Sahoo, whom as we reported in February lost four papers from Acta Biomaterialia for what the journal called “highly unethical practices,” has actually retracted five papers from that journal.

According to a notice for “Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin loaded cubic phase nanoparticles for cancer therapy” that appears in the June issue along with the other four:

Failure to reproduce experiments, errors lead to retraction of pancreatic cancer paper

The authors of a paper in Laboratory Investigation have retracted it after they were unable to “reproduce key experiments,” and discovered “several minor errors.”

Here’s the retraction notice for “Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling,” by Liqun Wu and colleagues of The Affiliated Hospital of Medical College, QingDao University, in China’s Shan Dong Province:

Two Expressions of Concern in Blood for MD Anderson’s Aggarwal, who has threatened to sue Retraction Watch

Bharat Aggarwal, the MD Anderson researcher who has threatened to sue us while under investigation by his institution for alleged misconduct, now has two Expressions of Concern in addition to two corrections and two unexplained withdrawals.

Both of the papers were published in Blood. The Expression of Concern for “Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway,” reads:

Authors retract CT scan-cancer paper, citing faulty data

A group of cancer researchers in Japan has retracted their 2011 paper in the journal Medicine. The reason: They seem to have had some trouble — well, perhaps a bit more than some — with their patient population.

The article, titled “Usefulness of systemic CT scanning in the detection of malignant lymphadenopathy,” came from the lab of Norio Komatsu, a hematologist at Juntendo University School of Medicine.

The paper’s no longer online, but we did find an abstract floating around:

Two cancer papers retracted because authors “are unable to guarantee the accuracy of some of the figures”

A team of researchers in Ireland has retracted two papers from Cancer Letters after concerns were apparently raised about some of the studies’ figures.

Denise Egan, of the Institute of Technology Tallaght in Dublin, and colleagues published “In vitro anti-tumour and cyto-selective effects of coumarin-3-carboxylic acid and three of its hydroxylated derivatives, along with their silver-based complexes, using human epithelial carcinoma cell lines” and “A study of the role of apoptotic cell death and cell cycle events mediating the mechanism of action of 6-hydroxycoumarin-3-carboxylatosilver in human malignant hepatic cells” in 2007.

The two notices say the same thing:

Without “confidence in the conclusions,” group retracts prostate cancer paper

Back in January, we wrote about the retraction of a paper in the International Journal of Radiation Oncology *Biology* Physics, the first from that journal in its 38-year history.

At the time, the journal’s new editor, Anthony Zietman, of Mass General, told us that he was working on a second retraction. That one has arrived.

The paper, “High-Dose Conformal Radiotherapy Reduces Prostate Cancer–Specific Mortality: Results of a Meta-analysis,” came from a team of radiation oncologists in Brazil, and was published last August.

According to the retraction notice:

ORI, OHRP find “some human subject issues” in Henschke lung cancer studies, but no evidence of misconduct

We have an update on two papers about lung cancer screening by Claudia Henschke and colleagues that were subject to an Expression of Concern early last year.

The original Expression of Concern in Cancer read, in part:

ORI rules in longstanding University of Washington misconduct case

Andrew Aprikyan

A case of alleged misconduct at the University of Washington in Seattle may finally be over. The Office of Research Integrity released its findings following an investigation into the work of Andrew Aprikyan, a former hematology researcher at the university.

The Aprikyan case has dragged on for a decade. In 2010, the university fired the scientist after a court denied his appeals based on allegations that they had denied him due process. As the Seattle Times reported at the time: 

The “unintentionality” of being leads to nothingness for paper on protein’s role in cancer

A group of cancer researchers in Argentina has retracted a paper on the p300 protein in breast cancer that appeared in Experimental and Molecular Pathology.

The article, titled “Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer,” was published in 2010 by Maria E. Fermento and colleagues. It has been cited 11 times since, according to Thomson Scientific’s Web of Knowledge.

Here’s the notice: